Sandeep Chhabra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandeep Chhabra has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Raymond S. Norton
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
17 shared publications - James D. Swarbrick
Biomedicine Discovery Institute, Infection Program and Department of Pharmacology and Infection Program and Department of Microbiology, Monash University, Melbourne, VIC 3800, Australia
7 shared publications - Michael W. Pennington
Ambiopharm Inc
7 shared publications - Christine Beeton
Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas 77030, USA
6 shared publications - Thomas S. Peat
Biomedical Program, CSIRO, 343 Royal Parade, Parkville, VIC 3052, Australia
6 shared publications - Haribabu Arthanari
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
5 shared publications
Latest Publications
- 28 April 2022
- Published by Elsevier in Materials Today: Proceedings
- Vol. 64, 1211-1216
Study of utilization of hydrogen as fuel in internal combustion engine
- 28 April 2022
- Published by Elsevier in Materials Today: Proceedings
- Vol. 64, 1211-1216
Study of utilization of hydrogen as fuel in internal combustion engine
- Open Access
- 6 May 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (25) , 13685
Cover Picture: Local Deuteration Enables NMR Observation of Methyl Groups in Proteins from Eukaryotic and Cell‐Free Expression Systems (Angew. Chem. Int. Ed. 25/2021)
- 6 May 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (25) , 13685
Open AccessCover Picture: Local Deuteration Enables NMR Observation of Methyl Groups in Proteins from Eukaryotic and Cell‐Free Expression Systems (Angew. Chem. Int. Ed. 25/2021)
- Open Access
- 6 May 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (25) , 13801
Titelbild: Lokale Deuterierung ermöglicht NMR‐Messung von Methylgruppen in Proteinen aus eukaryotischen und Zell‐freien Expressionssystemen (Angew. Chem. 25/2021)
- 6 May 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (25) , 13801
Open AccessTitelbild: Lokale Deuterierung ermöglicht NMR‐Messung von Methylgruppen in Proteinen aus eukaryotischen und Zell‐freien Expressionssystemen (Angew. Chem. 25/2021)
- 11 March 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (4) , 333-340
Aromatic 19F-13C TROSY: a background-free approach to probe biomolecular structure, function, and dynamics
Atomic-level information about the structure and dynamics of biomolecules is critical for an understanding of their function. Nuclear magnetic resonance (NMR) spectroscopy provides unique insights into the dynamic nature of biomolecules and their interactions, capturing transient conformers and their features. However, relaxation-induced line broadening and signal overlap make it challenging to apply NMR spectroscopy to large biological systems. Here we took advantage of the high sensitivity and broad chemical shift range of 19F nuclei and leveraged the remarkable relaxation properties of the aromatic 19F-13C spin pair to disperse 19F resonances in a two-dimensional transverse relaxation-optimized spectroscopy spectrum. We demonstrate the application of 19F-13C transverse relaxation-optimized spectroscopy to investigate proteins and nucleic acids. This experiment expands the scope of 19F NMR in the study of the structure, dynamics, and function of large and complex biological systems and provides a powerful background-free NMR probe.
- 11 March 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (4) , 333-340
Aromatic 19F-13C TROSY: a background-free approach to probe biomolecular structure, function, and dynamics
Atomic-level information about the structure and dynamics of biomolecules is critical for an understanding of their function. Nuclear magnetic resonance (NMR) spectroscopy provides unique insights into the dynamic nature of biomolecules and their interactions, capturing transient conformers and their features. However, relaxation-induced line broadening and signal overlap make it challenging to apply NMR spectroscopy to large biological systems. Here we took advantage of the high sensitivity and broad chemical shift range of 19F nuclei and leveraged the remarkable relaxation properties of the aromatic 19F-13C spin pair to disperse 19F resonances in a two-dimensional transverse relaxation-optimized spectroscopy spectrum. We demonstrate the application of 19F-13C transverse relaxation-optimized spectroscopy to investigate proteins and nucleic acids. This experiment expands the scope of 19F NMR in the study of the structure, dynamics, and function of large and complex biological systems and provides a powerful background-free NMR probe.
- 5 February 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (8) , 201717560-E1719
15 N detection harnesses the slow relaxation property of nitrogen: Delivering enhanced resolution for intrinsically disordered proteins
Significance: Intrinsically disordered proteins (IDPs) have attracted significant attention due to their roles in crucial cellular processes. NMR is the only technique that allows the study of IDPs at atomic-level resolution. However, narrow chemical shift dispersion, rapid exchange with solvent, and high proline content challenge conventional 1 H-detected experiments. Here, we report the development of a suite of 3D experiments based on 15 N direct detection that harnesses the slow relaxation and the larger chemical shift dispersion of 15 N nuclei for complete backbone assignment of IDPs, including proline residues, which are critical to the study of IDPs. Using this approach, we have assigned the regulatory domain of NFATC2 and have identified a likely mechanism by which 14-3-3 proteins regulate NFAT nuclear translocation.
- 5 February 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (8) , 201717560-E1719
15 N detection harnesses the slow relaxation property of nitrogen: Delivering enhanced resolution for intrinsically disordered proteins
Significance: Intrinsically disordered proteins (IDPs) have attracted significant attention due to their roles in crucial cellular processes. NMR is the only technique that allows the study of IDPs at atomic-level resolution. However, narrow chemical shift dispersion, rapid exchange with solvent, and high proline content challenge conventional 1 H-detected experiments. Here, we report the development of a suite of 3D experiments based on 15 N direct detection that harnesses the slow relaxation and the larger chemical shift dispersion of 15 N nuclei for complete backbone assignment of IDPs, including proline residues, which are critical to the study of IDPs. Using this approach, we have assigned the regulatory domain of NFATC2 and have identified a likely mechanism by which 14-3-3 proteins regulate NFAT nuclear translocation.
- Top Cited Papers
- 1 February 2018
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 8 (2) , 216-233
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the activity of T cells suppressed by PD-1. Here, we show that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) significantly enhances T-cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function. Although CDK4/6 inhibitors decrease T-cell proliferation, they increase tumor infiltration and activation of effector T cells. Moreover, CDK4/6 inhibition augments the response to PD-1 blockade in a novel ex vivo organotypic tumor spheroid culture system and in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. Significance: Our results define previously unrecognized immunomodulatory functions of CDK4/6 and suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may increase treatment efficacy in patients. Furthermore, our study highlights the critical importance of identifying complementary strategies to improve the efficacy of immunotherapy for patients with cancer. Cancer Discov; 8(2); 216–33. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Jenkins et al., p. 196. This article is highlighted in the In This Issue feature, p. 127
- 1 February 2018
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 8 (2) , 216-233
Top Cited PapersCDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the activity of T cells suppressed by PD-1. Here, we show that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) significantly enhances T-cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function. Although CDK4/6 inhibitors decrease T-cell proliferation, they increase tumor infiltration and activation of effector T cells. Moreover, CDK4/6 inhibition augments the response to PD-1 blockade in a novel ex vivo organotypic tumor spheroid culture system and in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. Significance: Our results define previously unrecognized immunomodulatory functions of CDK4/6 and suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may increase treatment efficacy in patients. Furthermore, our study highlights the critical importance of identifying complementary strategies to improve the efficacy of immunotherapy for patients with cancer. Cancer Discov; 8(2); 216–33. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Jenkins et al., p. 196. This article is highlighted in the In This Issue feature, p. 127
- 9 January 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 24 (8) , 1922-1930
8‐Mercaptoguanine Derivatives as Inhibitors of Dihydropteroate Synthase
Dihydropteroate synthase (DHPS) is an enzyme of the folate biosynthesis pathway, which catalyzes the formation of 7,8‐dihydropteroate (DHPt) from 6‐hydroxymethyl‐7,8‐dihydropterin pyrophosphate (DHPPP) and para‐aminobenzoic acid (pABA). DHPS is the long‐standing target of the sulfonamide class of antibiotics that compete with pABA. In the wake of sulfa drug resistance, targeting the structurally rigid (and more conserved) pterin site has been proposed as an alternate strategy to inhibit DHPS in wild‐type and sulfa drug resistant strains. Following the work on developing pterin‐site inhibitors of the adjacent enzyme 6‐hydroxymethyl‐7,8‐dihydropterin pyrophosphokinase (HPPK), we now present derivatives of 8‐mercaptoguanine, a fragment that binds weakly within both enzymes, and quantify sub‐μm binding using surface plasmon resonance (SPR) to Escherichia coli DHPS (EcDHPS). Eleven ligand‐bound EcDHPS crystal structures delineate the structure–activity relationship observed providing a structural framework for the rational development of novel, substrate‐envelope‐compliant DHPS inhibitors.
- 9 January 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 24 (8) , 1922-1930
8‐Mercaptoguanine Derivatives as Inhibitors of Dihydropteroate Synthase
Dihydropteroate synthase (DHPS) is an enzyme of the folate biosynthesis pathway, which catalyzes the formation of 7,8‐dihydropteroate (DHPt) from 6‐hydroxymethyl‐7,8‐dihydropterin pyrophosphate (DHPPP) and para‐aminobenzoic acid (pABA). DHPS is the long‐standing target of the sulfonamide class of antibiotics that compete with pABA. In the wake of sulfa drug resistance, targeting the structurally rigid (and more conserved) pterin site has been proposed as an alternate strategy to inhibit DHPS in wild‐type and sulfa drug resistant strains. Following the work on developing pterin‐site inhibitors of the adjacent enzyme 6‐hydroxymethyl‐7,8‐dihydropterin pyrophosphokinase (HPPK), we now present derivatives of 8‐mercaptoguanine, a fragment that binds weakly within both enzymes, and quantify sub‐μm binding using surface plasmon resonance (SPR) to Escherichia coli DHPS (EcDHPS). Eleven ligand‐bound EcDHPS crystal structures delineate the structure–activity relationship observed providing a structural framework for the rational development of novel, substrate‐envelope‐compliant DHPS inhibitors.
- Open Access
- 1 July 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (30) , 12599-12605
Reinvestigation of the biological activity of d-allo-ShK protein
- 1 July 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (30) , 12599-12605
Open AccessReinvestigation of the biological activity of d-allo-ShK protein
- Open Access
- 16 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 3756
Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats
The peptide HsTX1[R14A] is a potent and selective blocker of the voltage-gated potassium channel Kv1.3, which is a highly promising target for the treatment of autoimmune diseases and other conditions. In order to assess the biodistribution of this peptide, it was conjugated with NOTA and radiolabelled with copper-64. [64Cu]Cu-NOTA-HsTX1[R14A] was synthesised in high radiochemical purity and yield. The radiotracer was evaluatedin vitroandin vivo. The biodistribution and PET studies after intravenous and subcutaneous injections showed similar patterns and kinetics. The hydrophilic peptide was rapidly distributed, showed low accumulation in most of the organs and tissues, and demonstrated high molecular stabilityin vitroandin vivo. The most prominent accumulation occurred in the epiphyseal plates of trabecular bones. The high stability and bioavailability, low normal-tissue uptake of [64Cu]Cu-NOTA-HsTX1[R14A], and accumulation in regions of up-regulated Kv channels bothin vitroandin vivodemonstrate that HsTX1[R14A] represents a valuable lead for conditions treatable by blockade of the voltage-gated potassium channel Kv1.3. The pharmacokinetics shows that both intravenous and subcutaneous applications are viable routes for the delivery of this potent peptide.
- 16 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 3756
Open AccessDistribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats
The peptide HsTX1[R14A] is a potent and selective blocker of the voltage-gated potassium channel Kv1.3, which is a highly promising target for the treatment of autoimmune diseases and other conditions. In order to assess the biodistribution of this peptide, it was conjugated with NOTA and radiolabelled with copper-64. [64Cu]Cu-NOTA-HsTX1[R14A] was synthesised in high radiochemical purity and yield. The radiotracer was evaluatedin vitroandin vivo. The biodistribution and PET studies after intravenous and subcutaneous injections showed similar patterns and kinetics. The hydrophilic peptide was rapidly distributed, showed low accumulation in most of the organs and tissues, and demonstrated high molecular stabilityin vitroandin vivo. The most prominent accumulation occurred in the epiphyseal plates of trabecular bones. The high stability and bioavailability, low normal-tissue uptake of [64Cu]Cu-NOTA-HsTX1[R14A], and accumulation in regions of up-regulated Kv channels bothin vitroandin vivodemonstrate that HsTX1[R14A] represents a valuable lead for conditions treatable by blockade of the voltage-gated potassium channel Kv1.3. The pharmacokinetics shows that both intravenous and subcutaneous applications are viable routes for the delivery of this potent peptide.